BridgeBio Oncology Therapeutics, Inc.
No SEC Form 4 filings for $BBOT in the last 30 days.
See all $BBOT insider activity →BridgeBio Oncology Therapeutics (BBOT) reported 75% response rate for BBO-8520 with pembrolizumab in lung cancer patients. The company is focusing on combination therapies, with $344.1M cash runway. Q2 2026 net loss was $56.5M, up from $28.4M in Q2 2025. Key data readouts expected in mid-2027.
BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress • Continued to advance monotherapy and combination cohorts for all clinical programs • Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, in
Analyst estimates cited by FactSet show BridgeBio Oncology Therapeutics, Inc. average 12-month price target was cut to $24.89 from $25.30. The range is $18 to $41. Based on the Aug. 7 close, the target implies about 167% upside. Consensus remains “Buy” with 10 Buys and no Holds or Sells.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BBOT (BridgeBio Oncology Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent BBOT coverage spans financial news, technology and earnings.
Strong early efficacy could boost near‑term price if data hold up, but high cash burn and small sample size add risk.
The filing adds near-term clinical execution signals (new combination dosing) plus a quantified cash runway into 2028, which can shift risk/reward for the stock.
Analyst estimates cited by FactSet show BridgeBio Oncology Therapeutics, Inc. average 12-month price target was cut to $24.89 from $25.30. The range is $18 to $41. Based on the Aug. 7 close, the target implies about 167% upside. Consensus remains “Buy” with 10 Buys and no Holds or Sells.
Board refresh via director resignation and election; likely low immediate fundamental impact but can affect governance/oversight expectations.
This is not a catalyst-driven update; it mainly frames BBOT’s valuation, analyst target, and relative risk versus peers.
AlphAI scores every news story that mentions BBOT with an AI model for sentiment and relevance, and aggregates insider trades from BridgeBio Oncology Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BridgeBio Oncology Therapeutics (BBOT) reported 75% response rate for BBO-8520 with pembrolizumab in lung cancer patients. The company is focusing on combination therapies, with $344.1M cash runway. Q2 2026 net loss was $56.5M, up from $28.4M in Q2 2025. Key data readouts expected in mid-2027.
3 min readBridgeBio Oncology Therapeutics, Inc. (BBOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress • Continued to advance monotherapy and combination cohorts for all clinical programs • Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, in
4 min readAnalyst estimates cited by FactSet show BridgeBio Oncology Therapeutics, Inc. average 12-month price target was cut to $24.89 from $25.30. The range is $18 to $41. Based on the Aug. 7 close, the target implies about 167% upside. Consensus remains “Buy” with 10 Buys and no Holds or Sells.
1 min readBridgeBio Oncology Therapeutics, Inc. (BBOT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001869105 0001869105 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16,
3 min readThe article compares BridgeBio Oncology Therapeutics (BBOT) with competitors on profitability, risk, ownership, analyst views, and valuation. It cites BBOT’s beta of 0.22, 54.9% institutional ownership, and a consensus target price of $25.00 (MarketBeat), implying 178.71% upside. It says BBOT is more expensive on P/E and leads on 8 of 13 factors.
4 min readBridgeBio Oncology Therapeutics, Inc. (BBOT) has registered 63.05 million common shares for resale by existing securityholders through a post-effective amendment to its Form S-1. These shares include PIPE shares, shares issued during the Business Combination, and shares issuable upon option exercise. The company will not receive proceeds from these resales, except if options are exercised for cash.
2 min readBridgeBio Oncology Therapeutics (NASDAQ: BBOT) announced that two new employees hired in January 2026 were awarded 65,350 non-qualified stock options on February 10, 2026. The options have an exercise price of $10.84 per share and will vest 25% after one year, then monthly over 36 months, according to the company's 2025 Inducement Plan. This grant, approved by the compensation committee, is in compliance with Nasdaq Listing Rule 5635(c)(4).
2 min readSOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 ( GLOBE NEWSWIRE ) -- BridgeBio Oncology Therapeutics, Inc. ( "BBOT" ) ( Nasdaq: BBOT ) , a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data showing BBO-10203 selectively and specifically ...
3 min read
